Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoVaccine Technologies, a vaccine development company, has introduced DepoVax platform, a novel depot vaccine delivery system used to increase the efficacy and strength of vaccines. The company has also filed additional patents to protect the DepoVax concept.
Subscribe to our email newsletter
According to the company, DepoVax vaccines are readily amenable to commercialization. They can be manufactured in large batches, and are well suited for large scale distribution and long term storage. DepoVax vaccines are packaged and stored in a dry form, ensuring the stability of antigens which can otherwise be unstable in aqueous formulations.
DepoVax has been tested in pandemic influenza and therapeutic cancer models. The research shows DepoVax-vaccines deliver effective, long lasting results with only one dose.
Randal Chase, president and CEO of ImmunoVaccine Technologies (IVT), said: “An effective and easy-to-administer DepoVax vaccine would be a valuable tool for health authorities dealing with a pandemic and we are planning to take this into the clinic as soon as possible.”